FR18C1047I2 - Formulations a vecteur intracellulaires pour anthracycliniques et analogues cytidiniques - Google Patents

Formulations a vecteur intracellulaires pour anthracycliniques et analogues cytidiniques

Info

Publication number
FR18C1047I2
FR18C1047I2 FR18C1047C FR18C1047C FR18C1047I2 FR 18C1047 I2 FR18C1047 I2 FR 18C1047I2 FR 18C1047 C FR18C1047 C FR 18C1047C FR 18C1047 C FR18C1047 C FR 18C1047C FR 18C1047 I2 FR18C1047 I2 FR 18C1047I2
Authority
FR
France
Prior art keywords
anthracyclinics
vector formulations
cytidine analogues
intracellular vector
intracellular
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR18C1047C
Other languages
English (en)
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jazz Pharmaceuticals Therapeutics Inc
Original Assignee
Celator Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celator Pharmaceuticals Inc filed Critical Celator Pharmaceuticals Inc
Publication of FR18C1047I1 publication Critical patent/FR18C1047I1/fr
Application granted granted Critical
Publication of FR18C1047I2 publication Critical patent/FR18C1047I2/fr
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes
    • A61K9/1278—Post-loading, e.g. by ion or pH gradient
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/788—Of specified organic or carbon-based composition
    • Y10S977/797—Lipid particle
    • Y10S977/798—Lipid particle having internalized material
    • Y10S977/799—Containing biological material
    • Y10S977/801—Drug

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
FR18C1047C 2004-04-22 2018-11-14 Formulations a vecteur intracellulaires pour anthracycliniques et analogues cytidiniques Active FR18C1047I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56521004P 2004-04-22 2004-04-22
PCT/CA2005/000625 WO2005102359A1 (en) 2004-04-22 2005-04-22 Liposomal formulations of anthracycline agents and cytidine analogs

Publications (2)

Publication Number Publication Date
FR18C1047I1 FR18C1047I1 (fr) 2019-03-22
FR18C1047I2 true FR18C1047I2 (fr) 2019-10-04

Family

ID=35196733

Family Applications (1)

Application Number Title Priority Date Filing Date
FR18C1047C Active FR18C1047I2 (fr) 2004-04-22 2018-11-14 Formulations a vecteur intracellulaires pour anthracycliniques et analogues cytidiniques

Country Status (13)

Country Link
US (2) US8022279B2 (forum.php)
EP (2) EP1744764B1 (forum.php)
JP (1) JP4972545B2 (forum.php)
AU (1) AU2005235455B2 (forum.php)
BE (1) BE2018C045I2 (forum.php)
CA (1) CA2564542C (forum.php)
CY (2) CY1113012T1 (forum.php)
ES (1) ES2388064T3 (forum.php)
FR (1) FR18C1047I2 (forum.php)
IL (1) IL178779A (forum.php)
NL (1) NL300960I2 (forum.php)
PT (1) PT1744764E (forum.php)
WO (1) WO2005102359A1 (forum.php)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1796689A4 (en) * 2004-09-20 2009-01-14 British Columbia Cancer Agency GEMCITABINE FREE OR ENCAPSULATED IN LIPOSOMES ONLY OR IN ASSOCIATION WITH FREE IDARUBICIN OR ENCAPSULATED IN LIPOSOMES
EP2279726A3 (en) * 2005-05-26 2012-06-20 Biorest Ltd. Compositions and methods using same for delivering agents into a target organ protected by a blood barrier
PL2120568T3 (pl) * 2007-02-16 2018-03-30 Celator Pharmaceuticals, Inc. Stały stosunek leków w leczeniu krwiotwórczych nowotworów i chorób proliferacyjnych
WO2009106549A2 (en) * 2008-02-26 2009-09-03 Nerviano Medical Sciences S.R.L. Antitumor combination comprising a morpholinyl anthracycline derivative and demethylating agents
WO2011119995A2 (en) 2010-03-26 2011-09-29 Cerulean Pharma Inc. Formulations and methods of use
CN101912363A (zh) * 2010-07-29 2010-12-15 蔡海德 溶解超滤-喷雾干燥-分子分散包衣-水化制粒-冷冻干燥生产脂质体组合药物
PL2768484T3 (pl) * 2011-10-21 2019-12-31 Jazz Pharmaceuticals Research Llc Liofilizowane liposomy
SG11201406340QA (en) 2012-04-04 2014-11-27 Halozyme Inc Combination therapy with an anti - hyaluronan agent and a tumor - targeted taxane
MX370567B (es) * 2012-05-09 2019-12-17 Cantex Pharmaceuticals Inc Tratamiento de mielosupresion.
US10052346B2 (en) 2015-02-17 2018-08-21 Cantex Pharmaceuticals, Inc. Treatment of myelodysplastic syndromes with 2-O and,or 3-O desulfated heparinoids
WO2016177741A1 (en) 2015-05-04 2016-11-10 Eth Zurich Method for preparing transmembrane ph-gradient vesicles
MA43184A (fr) * 2015-11-02 2021-04-14 Fujifilm Corp Composition liposomale et son procédé de production
SG10202112699UA (en) 2015-11-11 2021-12-30 Celator Pharmaceuticals Inc Assays and methods for selecting a treatment regimen for a subject with leukemia
US12064445B2 (en) 2015-12-03 2024-08-20 Biosight Ltd. Cytarabine conjugates for cancer therapy
US12071450B2 (en) 2015-12-03 2024-08-27 Biosight Ltd. Salts of conjugates for cancer therapy
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US12186296B1 (en) 2016-07-22 2025-01-07 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
WO2019012328A1 (en) * 2017-07-09 2019-01-17 Biosight Pharma ANTICANCER POLY THERAPY
WO2019222435A1 (en) 2018-05-16 2019-11-21 Halozyme, Inc. Methods of selecting subjects for combination cancer therapy with a polymer-conjugated soluble ph20
CN113164502A (zh) 2018-09-25 2021-07-23 塞拉特药物股份有限公司 血液病的低强度治疗
BR112021013766A2 (pt) 2019-03-01 2021-09-21 Flamel Ireland Limited Composições de gama-hidroxibutirato com farmacocinética melhorada no estado alimentado
US11980636B2 (en) 2020-11-18 2024-05-14 Jazz Pharmaceuticals Ireland Limited Treatment of hematological disorders
CN113181117B (zh) * 2021-03-22 2022-08-26 沈阳药科大学 一种紫草素和蒽环类化疗药共载脂质体及其制备方法和应用
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
WO2025088367A1 (en) * 2023-10-27 2025-05-01 Jodas Expoim Pvt. Ltd Liposomal composition of idarubicin and cytarabine and process for preparation thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3993754A (en) 1974-10-09 1976-11-23 The United States Of America As Represented By The United States Energy Research And Development Administration Liposome-encapsulated actinomycin for cancer chemotherapy
US4086257A (en) 1976-10-12 1978-04-25 Sears Barry D Phosphatidyl quaternary ammonium compounds
CH624011A5 (forum.php) 1977-08-05 1981-07-15 Battelle Memorial Institute
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4522803A (en) 1983-02-04 1985-06-11 The Liposome Company, Inc. Stable plurilamellar vesicles, their preparation and use
US4588578A (en) 1983-08-08 1986-05-13 The Liposome Company, Inc. Lipid vesicles prepared in a monophase
US5077056A (en) 1984-08-08 1991-12-31 The Liposome Company, Inc. Encapsulation of antineoplastic agents in liposomes
US5736155A (en) * 1984-08-08 1998-04-07 The Liposome Company, Inc. Encapsulation of antineoplastic agents in liposomes
US5059421A (en) 1985-07-26 1991-10-22 The Liposome Company, Inc. Preparation of targeted liposome systems of a defined size distribution
MX9203808A (es) 1987-03-05 1992-07-01 Liposome Co Inc Formulaciones de alto contenido de medicamento: lipido, de agentes liposomicos-antineoplasticos.
US5800833A (en) 1995-02-27 1998-09-01 University Of British Columbia Method for loading lipid vesicles
GB9613182D0 (en) 1996-06-24 1996-08-28 Nycomed Imaging As Method
US5837282A (en) 1996-10-30 1998-11-17 University Of British Columbia Ionophore-mediated liposome loading
US6146659A (en) * 1998-07-01 2000-11-14 Neopharm, Inc. Method of administering liposomal encapsulated taxane
ES2186484B1 (es) 2000-10-10 2004-07-01 Lipotec, S.A. Liposomas encapsulando farmacos anticancerosos y uso de los mismos en el tratamiento de tumores malignos.
US6613753B2 (en) 2001-02-21 2003-09-02 Supergen, Inc. Restore cancer-suppressing functions to neoplastic cells through DNA hypomethylation
CA2383259A1 (en) * 2002-04-23 2003-10-23 Celator Technologies Inc. Synergistic compositions
EP1432403B1 (en) * 2001-10-03 2010-07-28 Celator Pharmaceuticals, Inc. Liposome loading with metal ions
US7850990B2 (en) 2001-10-03 2010-12-14 Celator Pharmaceuticals, Inc. Compositions for delivery of drug combinations
CA2536612A1 (en) * 2003-04-02 2004-10-14 Celator Pharmaceuticals, Inc. Combination compositions of camptothecins and fluoropyrimidines
US20060165744A1 (en) 2003-05-22 2006-07-27 Neopharm, Inc Combination liposomal formulations

Also Published As

Publication number Publication date
JP2007533670A (ja) 2007-11-22
WO2005102359A1 (en) 2005-11-03
US20120009252A1 (en) 2012-01-12
EP1744764A4 (en) 2009-04-01
EP2407169A1 (en) 2012-01-18
CA2564542A1 (en) 2005-11-03
AU2005235455A1 (en) 2005-11-03
WO2005102359A8 (en) 2005-12-15
HK1097194A1 (en) 2007-06-22
NL300960I2 (nl) 2019-05-22
CY2018033I2 (el) 2019-07-10
CY1113012T1 (el) 2016-04-13
FR18C1047I1 (fr) 2019-03-22
EP1744764B1 (en) 2012-05-30
PT1744764E (pt) 2012-08-30
JP4972545B2 (ja) 2012-07-11
IL178779A (en) 2013-12-31
US8431806B2 (en) 2013-04-30
CY2018033I1 (el) 2019-07-10
CA2564542C (en) 2012-11-27
US20070286897A1 (en) 2007-12-13
EP1744764A1 (en) 2007-01-24
US8022279B2 (en) 2011-09-20
BE2018C045I2 (forum.php) 2024-08-08
IL178779A0 (en) 2007-05-15
ES2388064T3 (es) 2012-10-08
AU2005235455B2 (en) 2011-01-20

Similar Documents

Publication Publication Date Title
FR18C1047I2 (fr) Formulations a vecteur intracellulaires pour anthracycliniques et analogues cytidiniques
FIC20240007I1 (fi) Gefapiksantti tai sen farmaseuttisesti hyväksyttävä suola
DE602005015466D1 (de) Antivirale 4'-azidonucleoside
DK1812025T3 (da) Stabiliserede bakteriofagformuleringer
DK1819670T3 (da) 12-Aryl-prostaglandinanaloger
MA29014B1 (fr) Formulations d'anticorps
DE50306910D1 (de) Dreidimensionale knotenstruktur
EP1784219A4 (en) STABILIZING FORMULATIONS
GB0418172D0 (en) Vector
IS7861A (is) Sjávar lípíða samsetningar
IL178596A0 (en) Sustained release formulations
DE60327330D1 (de) Giessdüse
GB0427001D0 (en) Vector
IL183109A0 (en) Antiinfective lipopeptides
DE502004005390D1 (de) Verzögerungsregelkreis
EP1728504A4 (en) EMULSION STABILIZER
EP1616957A4 (en) VECTOR
NO20045424D0 (no) Ingrediensbeholder
EP1756276A4 (en) KRUST ANIMAL EXPRESSION VECTOR
PL378439A1 (pl) Środki depigmentujące
FR2866666B1 (fr) About d'echafaudage
FR2855509B1 (fr) Sangle ventrale ergonomique pour equides
MA28462B1 (fr) Formulations pour inhalation
UA11612S (uk) Упаковка для пельменів «малюк»
ITMN20040010A1 (it) Portamenu'